Eczema patients lack natural antibiotic in skin

Researchers at National Jewish Medical and Research Center report in the October 10 issue of the New England Journal of Medicine that patients with atopic dermatitis, also known as eczema, are susceptible to bacterial infections of their skin because they fail to produce effective amounts of two antimicrobial peptides. The findings demonstrate for the first time the clinical significance of these peptides in humans, and suggest that a medication containing or inducing the peptides may one day be used to fight the infections that plague millions of atopic dermatitis patients. The accompanying editorial in the journal called it a "seminal study."

"This study helps explain why 90 percent of atopic dermatitis patients are colonized by staphylococcus aureus and 30 percent develop active infections," said the study's senior author, Donald Leung, M.D., Ph.D., Head of Pediatric Allergy-Immunology at National Jewish Medical and Research Center, in Denver. "It is important to understand why people with this common skin disease are so susceptible to skin infections, especially in light of recent widespread concerns that they can develop severe infections after receiving a smallpox vaccination. Interestingly, these antimicrobial peptides are also needed to combat viral infections and therefore could account for the susceptibility of atopic dermatitis patients to eczema vaccinatum and herpes simplex infections."

Atopic dermatitis is a common, chronic skin disease characterized by dry, itchy and easily irritated skin. It occurs most commonly in infants and young children, but can persist into adulthood. Severe cases can lead to sleep deprivation, chronic bacterial infections, and depression. Approximately one in nine people in the United States suffer from this disease at some point. Along with other allergic diseases, its prevalence has grown significantly in recent years.

Immunologists recently identified peptides in the skin that help fight incipient in

Contact: William Allstetter
National Jewish Medical and Research Center

Page: 1 2 3

Related biology news :

1. Trial shows which brain cancer patients benefit from temozolomide
2. Study of flu patients reveals virus outsmarting key drug
3. Decreasing toxins in brains of Alzheimers patients keep cognitive deficits at bay
4. Activated signaling pathway may predict lung cancer patients response to gefitinib
5. Targeted therapy for lung cancer patients shows promise in extending lives
6. Breast cancer patients failed by treatment with taxol and taxotere respond to abraxane
7. Study finds that only half of a commonly used cancer drug is activated in cancer patients
8. APP reports Abraxane(TM) is active in breast cancer patients who failed taxol or taxotere
9. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
10. Lung cancer patients in Japan, United States react differently to the same chemotherapy regimen
11. Gene expression ratio identifies risk of recurrence in breast cancer patients receiving tamoxifen

Post Your Comments:

(Date:11/20/2015)... OXFORD, Connecticut , November 20, 2015 ... biometric authentication company focused on the growing mobile commerce ... its CEO, Gino Pereira , was recently interviewed ... The interview will air on this weekend on ... Bloomberg Latin America . --> NXTD ) ...
(Date:11/19/2015)... 2015  Based on its in-depth analysis of the ... with the 2015 Global Frost & Sullivan Award for ... presents this award to the company that has developed ... of the market it serves. The award recognizes the ... on customer base demands, the overall impact it has ...
(Date:11/19/2015)... 19, 2015  Although some 350 companies are actively ... a few companies, according to Kalorama Information. These include Roche ... the market share of the 6.1 billion-dollar molecular testing ... Market for Molecular Diagnostic s .    ... still controlled by one company and only a handful ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. 25, ... HART ), a biotechnology company developing bioengineered organ ... Jim McGorry will present at the LD Micro ... at 2:30 p.m. PT. The presentation will be webcast ... days. Management will also be available at the conference ...
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . http://www.neurocrine.com .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership ... Professionals (OPBAP) has been formalized with the signing of a Memorandum of Understanding. ... OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, ...
Breaking Biology Technology:
Cached News: